Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network

M. Rondy; J. Castilla; O. Launay; S. Costanzo; C. Ezpeleta; F. Galtier; K. de Gaetano Donati; Carmen Ezpeleta; A. Moren; Xabier Beristain; Judith Chamorro; Mercedes Gabari; Pilar Artajo; Francisco Lameiro; Laura Barrado; Maite Ortega; Montse Torres; José Javier García Irure; Fátima Irisarri; Manuel García Cenoz; Marcela Guevara; Itziar Casado; Jorge Díaz; Iván Martínez-Baz; Jesús Castilla; Nezha Lenzi; Zineb Lesieur; Isabelle Bonmarin; Corinne Merle; Vincent Foulongne; Flavie Letois; Valérie Driss; Philippe Géraud; Arnaud Bourdin; Liliane Landreau; Amadou Konaté; Philippe Corne; Mustapha Sebbane; Kada Klouche; Marie Suzanne Léglise; Pierre Loulergue; Reem Kanaan; Florence Dumas; Anne Krivine; Sonia Moncilovic; Nadine Ali; Xavier Duval; Yolande Costa; Rachid Aït Naman; Yazdan Yazdapanah; Marion Caseris; Nathalie Dournon; Thomas Papo; Antoine Dossier; Hakim Bécheur; Anne Laure Pelletier; Hervé Mal; Armelle Marceau; Michel Aubier; Raphaêl Bories; Enrique Casalino; Christophe Choquet; Nadhira Houhou; Philippe Vanhems; Corinne Régis; Stéphane Jouneau; Fabrice Lainé; Pierre Tattevin; Luc Beuzit; Elise Thébault; Sophie Fey; Gisele Lagathu et Sophie Cha; Déborah Postil; Sébastien Alcoléa; Sylvie Rogez; Martine Valette; Bruno Lina; Katleen de Gaetano Donati; Roberto Cauda; Francesco Taccari; Rosaria Santangelo; Francesco Perlasca; Giovanni Fichera; Marianna Dara; Simona Costanzo; Licia Iacoviello; Marco Olivieri

doi:10.1080/21645515.2015.1126013

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network

M. Rondy, J. Castilla, O. Launay, S. Costanzo, C. Ezpeleta, F. Galtier, K. de Gaetano Donati, Carmen Ezpeleta, A. Moren, Xabier Beristain, Judith Chamorro, Mercedes Gabari, Pilar Artajo, Francisco Lameiro, Laura Barrado, Maite Ortega, Montse Torres, José Javier García Irure, Fátima Irisarri, Manuel García CenozMarcela Guevara, Itziar Casado, Jorge Díaz, Iván Martínez-Baz, Jesús Castilla, Nezha Lenzi, Zineb Lesieur, Isabelle Bonmarin, Corinne Merle, Vincent Foulongne, Flavie Letois, Valérie Driss, Philippe Géraud, Arnaud Bourdin, Liliane Landreau, Amadou Konaté, Philippe Corne, Mustapha Sebbane, Kada Klouche, Marie Suzanne Léglise, Pierre Loulergue, Reem Kanaan, Florence Dumas, Anne Krivine, Sonia Moncilovic, Nadine Ali, Xavier Duval, Yolande Costa, Rachid Aït Naman, Yazdan Yazdapanah, Marion Caseris, Nathalie Dournon, Thomas Papo, Antoine Dossier, Hakim Bécheur, Anne Laure Pelletier, Hervé Mal, Armelle Marceau, Michel Aubier, Raphaêl Bories, Enrique Casalino, Christophe Choquet, Nadhira Houhou, Philippe Vanhems, Corinne Régis, Stéphane Jouneau, Fabrice Lainé, Pierre Tattevin, Luc Beuzit, Elise Thébault, Sophie Fey, Gisele Lagathu et Sophie Cha, Déborah Postil, Sébastien Alcoléa, Sylvie Rogez, Martine Valette, Bruno Lina, Katleen de Gaetano Donati, Roberto Cauda, Francesco Taccari, Rosaria Santangelo, Francesco Perlasca, Giovanni Fichera, Marianna Dara, Simona Costanzo, Licia Iacoviello, Marco Olivieri

www.neuromed.it

Research output: Contribution to journal › Article › peer-review

Abstract

We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.

Original language	English
Pages (from-to)	1217-1224
Number of pages	8
Journal	Human Vaccines and Immunotherapeutics
Volume	12
Issue number	5
DOIs	https://doi.org/10.1080/21645515.2015.1126013
Publication status	Published - May 3 2016

Keywords

case control studies
hospital
Influenza
Influenza vaccine
multicentre studies

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pharmacology

Access to Document

10.1080/21645515.2015.1126013

Fingerprint Dive into the research topics of 'Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network'. Together they form a unique fingerprint.

Cite this

Rondy, M., Castilla, J., Launay, O., Costanzo, S., Ezpeleta, C., Galtier, F., de Gaetano Donati, K., Ezpeleta, C., Moren, A., Beristain, X., Chamorro, J., Gabari, M., Artajo, P., Lameiro, F., Barrado, L., Ortega, M., Torres, M., García Irure, J. J., Irisarri, F., ... Olivieri, M. (2016). Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network. Human Vaccines and Immunotherapeutics, 12(5), 1217-1224. https://doi.org/10.1080/21645515.2015.1126013

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14 : Results from the InNHOVE network. / Rondy, M.; Castilla, J.; Launay, O.; Costanzo, S.; Ezpeleta, C.; Galtier, F.; de Gaetano Donati, K.; Ezpeleta, Carmen; Moren, A.; Beristain, Xabier; Chamorro, Judith; Gabari, Mercedes; Artajo, Pilar; Lameiro, Francisco; Barrado, Laura; Ortega, Maite; Torres, Montse; García Irure, José Javier; Irisarri, Fátima; García Cenoz, Manuel; Guevara, Marcela; Casado, Itziar; Díaz, Jorge; Martínez-Baz, Iván; Castilla, Jesús; Lenzi, Nezha; Lesieur, Zineb; Bonmarin, Isabelle; Merle, Corinne; Foulongne, Vincent; Letois, Flavie; Driss, Valérie; Géraud, Philippe; Bourdin, Arnaud; Landreau, Liliane; Konaté, Amadou; Corne, Philippe; Sebbane, Mustapha; Klouche, Kada; Léglise, Marie Suzanne; Loulergue, Pierre; Kanaan, Reem; Dumas, Florence; Krivine, Anne; Moncilovic, Sonia; Ali, Nadine; Duval, Xavier; Costa, Yolande; Aït Naman, Rachid; Yazdapanah, Yazdan; Caseris, Marion; Dournon, Nathalie; Papo, Thomas; Dossier, Antoine; Bécheur, Hakim; Pelletier, Anne Laure; Mal, Hervé; Marceau, Armelle; Aubier, Michel; Bories, Raphaêl; Casalino, Enrique; Choquet, Christophe; Houhou, Nadhira; Vanhems, Philippe; Régis, Corinne; Jouneau, Stéphane; Lainé, Fabrice; Tattevin, Pierre; Beuzit, Luc; Thébault, Elise; Fey, Sophie; Lagathu et Sophie Cha, Gisele; Postil, Déborah; Alcoléa, Sébastien; Rogez, Sylvie; Valette, Martine; Lina, Bruno; de Gaetano Donati, Katleen; Cauda, Roberto; Taccari, Francesco; Santangelo, Rosaria; Perlasca, Francesco; Fichera, Giovanni; Dara, Marianna; Costanzo, Simona ; Iacoviello, Licia; Olivieri, Marco.

In: Human Vaccines and Immunotherapeutics, Vol. 12, No. 5, 03.05.2016, p. 1217-1224.

Research output: Contribution to journal › Article › peer-review

Rondy, M, Castilla, J, Launay, O, Costanzo, S, Ezpeleta, C, Galtier, F, de Gaetano Donati, K, Ezpeleta, C, Moren, A, Beristain, X, Chamorro, J, Gabari, M, Artajo, P, Lameiro, F, Barrado, L, Ortega, M, Torres, M, García Irure, JJ, Irisarri, F, García Cenoz, M, Guevara, M, Casado, I, Díaz, J, Martínez-Baz, I, Castilla, J, Lenzi, N, Lesieur, Z, Bonmarin, I, Merle, C, Foulongne, V, Letois, F, Driss, V, Géraud, P, Bourdin, A, Landreau, L, Konaté, A, Corne, P, Sebbane, M, Klouche, K, Léglise, MS, Loulergue, P, Kanaan, R, Dumas, F, Krivine, A, Moncilovic, S, Ali, N, Duval, X, Costa, Y, Aït Naman, R, Yazdapanah, Y, Caseris, M, Dournon, N, Papo, T, Dossier, A, Bécheur, H, Pelletier, AL, Mal, H, Marceau, A, Aubier, M, Bories, R, Casalino, E, Choquet, C, Houhou, N, Vanhems, P, Régis, C, Jouneau, S, Lainé, F, Tattevin, P, Beuzit, L, Thébault, E, Fey, S, Lagathu et Sophie Cha, G, Postil, D, Alcoléa, S, Rogez, S, Valette, M, Lina, B, de Gaetano Donati, K, Cauda, R, Taccari, F, Santangelo, R, Perlasca, F, Fichera, G, Dara, M, Costanzo, S , Iacoviello, L & Olivieri, M 2016, 'Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network', Human Vaccines and Immunotherapeutics, vol. 12, no. 5, pp. 1217-1224. https://doi.org/10.1080/21645515.2015.1126013

Rondy, M. ; Castilla, J. ; Launay, O. ; Costanzo, S. ; Ezpeleta, C. ; Galtier, F. ; de Gaetano Donati, K. ; Ezpeleta, Carmen ; Moren, A. ; Beristain, Xabier ; Chamorro, Judith ; Gabari, Mercedes ; Artajo, Pilar ; Lameiro, Francisco ; Barrado, Laura ; Ortega, Maite ; Torres, Montse ; García Irure, José Javier ; Irisarri, Fátima ; García Cenoz, Manuel ; Guevara, Marcela ; Casado, Itziar ; Díaz, Jorge ; Martínez-Baz, Iván ; Castilla, Jesús ; Lenzi, Nezha ; Lesieur, Zineb ; Bonmarin, Isabelle ; Merle, Corinne ; Foulongne, Vincent ; Letois, Flavie ; Driss, Valérie ; Géraud, Philippe ; Bourdin, Arnaud ; Landreau, Liliane ; Konaté, Amadou ; Corne, Philippe ; Sebbane, Mustapha ; Klouche, Kada ; Léglise, Marie Suzanne ; Loulergue, Pierre ; Kanaan, Reem ; Dumas, Florence ; Krivine, Anne ; Moncilovic, Sonia ; Ali, Nadine ; Duval, Xavier ; Costa, Yolande ; Aït Naman, Rachid ; Yazdapanah, Yazdan ; Caseris, Marion ; Dournon, Nathalie ; Papo, Thomas ; Dossier, Antoine ; Bécheur, Hakim ; Pelletier, Anne Laure ; Mal, Hervé ; Marceau, Armelle ; Aubier, Michel ; Bories, Raphaêl ; Casalino, Enrique ; Choquet, Christophe ; Houhou, Nadhira ; Vanhems, Philippe ; Régis, Corinne ; Jouneau, Stéphane ; Lainé, Fabrice ; Tattevin, Pierre ; Beuzit, Luc ; Thébault, Elise ; Fey, Sophie ; Lagathu et Sophie Cha, Gisele ; Postil, Déborah ; Alcoléa, Sébastien ; Rogez, Sylvie ; Valette, Martine ; Lina, Bruno ; de Gaetano Donati, Katleen ; Cauda, Roberto ; Taccari, Francesco ; Santangelo, Rosaria ; Perlasca, Francesco ; Fichera, Giovanni ; Dara, Marianna ; Costanzo, Simona ; Iacoviello, Licia ; Olivieri, Marco. / Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14 : Results from the InNHOVE network. In: Human Vaccines and Immunotherapeutics. 2016 ; Vol. 12, No. 5. pp. 1217-1224.

@article{5fce06bae26e48cfafa038db37e7bc73,

title = "Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network",

abstract = "We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.",

keywords = "case control studies, hospital, Influenza, Influenza vaccine, multicentre studies",

author = "M. Rondy and J. Castilla and O. Launay and S. Costanzo and C. Ezpeleta and F. Galtier and {de Gaetano Donati}, K. and Carmen Ezpeleta and A. Moren and Xabier Beristain and Judith Chamorro and Mercedes Gabari and Pilar Artajo and Francisco Lameiro and Laura Barrado and Maite Ortega and Montse Torres and {Garc{\'i}a Irure}, {Jos{\'e} Javier} and F{\'a}tima Irisarri and {Garc{\'i}a Cenoz}, Manuel and Marcela Guevara and Itziar Casado and Jorge D{\'i}az and Iv{\'a}n Mart{\'i}nez-Baz and Jes{\'u}s Castilla and Nezha Lenzi and Zineb Lesieur and Isabelle Bonmarin and Corinne Merle and Vincent Foulongne and Flavie Letois and Val{\'e}rie Driss and Philippe G{\'e}raud and Arnaud Bourdin and Liliane Landreau and Amadou Konat{\'e} and Philippe Corne and Mustapha Sebbane and Kada Klouche and L{\'e}glise, {Marie Suzanne} and Pierre Loulergue and Reem Kanaan and Florence Dumas and Anne Krivine and Sonia Moncilovic and Nadine Ali and Xavier Duval and Yolande Costa and {A{\"i}t Naman}, Rachid and Yazdan Yazdapanah and Marion Caseris and Nathalie Dournon and Thomas Papo and Antoine Dossier and Hakim B{\'e}cheur and Pelletier, {Anne Laure} and Herv{\'e} Mal and Armelle Marceau and Michel Aubier and Rapha{\^e}l Bories and Enrique Casalino and Christophe Choquet and Nadhira Houhou and Philippe Vanhems and Corinne R{\'e}gis and St{\'e}phane Jouneau and Fabrice Lain{\'e} and Pierre Tattevin and Luc Beuzit and Elise Th{\'e}bault and Sophie Fey and {Lagathu et Sophie Cha}, Gisele and D{\'e}borah Postil and S{\'e}bastien Alcol{\'e}a and Sylvie Rogez and Martine Valette and Bruno Lina and {de Gaetano Donati}, Katleen and Roberto Cauda and Francesco Taccari and Rosaria Santangelo and Francesco Perlasca and Giovanni Fichera and Marianna Dara and Simona Costanzo and Licia Iacoviello and Marco Olivieri",

year = "2016",

month = may,

day = "3",

doi = "10.1080/21645515.2015.1126013",

language = "English",

volume = "12",

pages = "1217--1224",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

publisher = "Taylor and Francis Inc.",

number = "5",

}

TY - JOUR

T1 - Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14

T2 - Results from the InNHOVE network

AU - Rondy, M.

AU - Castilla, J.

AU - Launay, O.

AU - Costanzo, S.

AU - Ezpeleta, C.

AU - Galtier, F.

AU - de Gaetano Donati, K.

AU - Ezpeleta, Carmen

AU - Moren, A.

AU - Beristain, Xabier

AU - Chamorro, Judith

AU - Gabari, Mercedes

AU - Artajo, Pilar

AU - Lameiro, Francisco

AU - Barrado, Laura

AU - Ortega, Maite

AU - Torres, Montse

AU - García Irure, José Javier

AU - Irisarri, Fátima

AU - García Cenoz, Manuel

AU - Guevara, Marcela

AU - Casado, Itziar

AU - Díaz, Jorge

AU - Martínez-Baz, Iván

AU - Castilla, Jesús

AU - Lenzi, Nezha

AU - Lesieur, Zineb

AU - Bonmarin, Isabelle

AU - Merle, Corinne

AU - Foulongne, Vincent

AU - Letois, Flavie

AU - Driss, Valérie

AU - Géraud, Philippe

AU - Bourdin, Arnaud

AU - Landreau, Liliane

AU - Konaté, Amadou

AU - Corne, Philippe

AU - Sebbane, Mustapha

AU - Klouche, Kada

AU - Léglise, Marie Suzanne

AU - Loulergue, Pierre

AU - Kanaan, Reem

AU - Dumas, Florence

AU - Krivine, Anne

AU - Moncilovic, Sonia

AU - Ali, Nadine

AU - Duval, Xavier

AU - Costa, Yolande

AU - Aït Naman, Rachid

AU - Yazdapanah, Yazdan

AU - Caseris, Marion

AU - Dournon, Nathalie

AU - Papo, Thomas

AU - Dossier, Antoine

AU - Bécheur, Hakim

AU - Pelletier, Anne Laure

AU - Mal, Hervé

AU - Marceau, Armelle

AU - Aubier, Michel

AU - Bories, Raphaêl

AU - Casalino, Enrique

AU - Choquet, Christophe

AU - Houhou, Nadhira

AU - Vanhems, Philippe

AU - Régis, Corinne

AU - Jouneau, Stéphane

AU - Lainé, Fabrice

AU - Tattevin, Pierre

AU - Beuzit, Luc

AU - Thébault, Elise

AU - Fey, Sophie

AU - Lagathu et Sophie Cha, Gisele

AU - Postil, Déborah

AU - Alcoléa, Sébastien

AU - Rogez, Sylvie

AU - Valette, Martine

AU - Lina, Bruno

AU - de Gaetano Donati, Katleen

AU - Cauda, Roberto

AU - Taccari, Francesco

AU - Santangelo, Rosaria

AU - Perlasca, Francesco

AU - Fichera, Giovanni

AU - Dara, Marianna

AU - Costanzo, Simona

AU - Iacoviello, Licia

AU - Olivieri, Marco

PY - 2016/5/3

Y1 - 2016/5/3

N2 - We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.

AB - We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.

KW - case control studies

KW - hospital

KW - Influenza

KW - Influenza vaccine

KW - multicentre studies

UR - http://www.scopus.com/inward/record.url?scp=84976415449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976415449&partnerID=8YFLogxK

U2 - 10.1080/21645515.2015.1126013

DO - 10.1080/21645515.2015.1126013

M3 - Article

AN - SCOPUS:84976415449

VL - 12

SP - 1217

EP - 1224

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 5

ER -